ReviewCureus2026
Calcium Hydroxyapatite for Gingival Phenotype Enhancement: A Translational Review and Clinical Decision-Making Framework.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft-tissue deficiencies, including interdental papilla loss and thin gingival phenotypes, remain challenging to manage predictably in periodontology. While hyaluronic acid fillers provide transient volumetric improvement, calcium hydroxyapatite (CaHA) is a biostimulatory injectable biomaterial capable of inducing extracellular matrix remodeling and sustained soft-tissue reinforcement. This review evaluates the biological rationale and available evidence supporting CaHA and explores its potential role in periodontal soft-tissue management. A narrative review was conducted in accordance with the Scale for the Assessment of Narrative Review Articles (SANRA) recommendations. A structured search of PubMed, Scopus, and Google Scholar identified studies published from 2020 to 2025 investigating injectable CaHA in soft-tissue applications. Evidence from dermatology, aesthetic medicine, biomaterials, and histological research was synthesized to assess the biological mechanisms, tissue responses, and translational relevance of CaHA to gingival tissues. CaHA demonstrates a dual mechanism combining immediate volumization with delayed biostimulation through fibroblast activation, neocollagenesis, and extracellular matrix remodeling. Evidence from extraoral applications consistently reports increased tissue thickness, improved mechanical properties, and sustained clinical effects. Preliminary reports in periodontal contexts suggest potential for interdental papilla augmentation in mild defects; however, available data remain limited by small sample sizes, short follow-up, and lack of standardized protocols or histological validation. Current evidence supports the biological plausibility of CaHA as an adjunctive approach for soft-tissue reinforcement rather than defect correction. Its potential role appears most relevant in thin gingival phenotypes and mild papillary deficiencies, where increased tissue thickness and stability are desired. However, the available evidence is derived predominantly from non-periodontal studies, and the absence of controlled periodontal investigations precludes routine clinical use. Accordingly, the application of CaHA in periodontology should currently be regarded as experimental until validated by dedicated preclinical and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.